Stability requirements – ICH and WHO guidelines MCQs With Answer

Introduction: Stability requirements – ICH and WHO guidelines MCQs With Answer is a focused resource designed for M.Pharm students preparing for exams and regulatory practice. This set of questions covers core aspects of ICH and WHO stability guidance: long‑term, intermediate and accelerated testing conditions, climatic zones, photostability, forced degradation, bracketing and matrixing designs, analytical method requirements, and stability considerations for biologicals and vaccines. Questions emphasize regulatory expectations, study design, data evaluation and practical implications for formulation and packaging. Each MCQ includes plausible distractors and clear answers to help reinforce concepts needed for regulatory filings, stability study planning, and interpretation of stability data in real‑world pharmaceutical development.

Q1. Which topic is the primary focus of the ICH Q1A(R2) guideline?

• Quality target product profile for pharmaceuticals
• Stability testing of new drug substances and products
• Good manufacturing practice requirements
• Pharmacovigilance reporting timelines

Correct Answer: Stability testing of new drug substances and products

Q2. What are the ICH-recommended long-term and accelerated stability conditions for products intended for general climatic zones (e.g., Zone II/I)?

• 30°C ±2°C/65% RH ±5% for long-term and 50°C ±5°C for accelerated
• 25°C ±2°C/60% RH ±5% for long-term and 40°C ±2°C/75% RH ±5% for accelerated
• 5°C ±3°C for long-term and 25°C ±2°C/60% RH ±5% for accelerated
• 40°C ±2°C/25% RH ±5% for long-term and 60°C ±5°C for accelerated

Correct Answer: 25°C ±2°C/60% RH ±5% for long-term and 40°C ±2°C/75% RH ±5% for accelerated

Q3. According to ICH Q1B, what minimum light exposure is recommended for photostability testing of new drug products?

• 100,000 lux hours and 50 watt-hours/m²
• 1.2 million lux hours and an integrated near-UV energy of not less than 200 watt-hours/m²
• 10 million lux hours and 1,000 watt-hours/m²
• No specific numerical exposure; only natural sunlight testing is required

Correct Answer: 1.2 million lux hours and an integrated near-UV energy of not less than 200 watt-hours/m²

Q4. Which statement best describes “bracketing” and “matrixing” designs in stability studies?

• Bracketing tests all intermediates; matrixing tests every strength and container size
• Bracketing tests only extremes of design factors; matrixing tests a reduced, statistically designed subset of samples
• Bracketing and matrixing are synonymous and interchangeable terms
• Matrixing tests only accelerated conditions while bracketing tests only long-term conditions

Correct Answer: Bracketing tests only extremes of design factors; matrixing tests a reduced, statistically designed subset of samples

Q5. What is the primary objective of forced degradation (stress) studies during stability assessment?

• To determine clinical efficacy after storage
• To accelerate product expiry for market withdrawal
• To identify degradation pathways and help develop stability‑indicating analytical methods
• To determine primary packaging color suitability

Correct Answer: To identify degradation pathways and help develop stability‑indicating analytical methods

Q6. For products intended for climatic Zone IVa, which long-term storage condition is typically recommended by ICH?

• 5°C ±3°C
• 25°C ±2°C/60% RH ±5%
• 30°C ±2°C/65% RH ±5%
• 40°C ±2°C/75% RH ±5%

Correct Answer: 30°C ±2°C/65% RH ±5%

Q7. When accelerated stability data indicate significant change, which condition is recommended by ICH Q1A as an intermediate test?

• 40°C ±2°C/75% RH ±5%
• 30°C ±2°C/65% RH ±5%
• 5°C ±3°C
• 60°C dry heat for 30 days

Correct Answer: 30°C ±2°C/65% RH ±5%

Q8. How does a “retest period” differ from a “shelf life” in regulatory stability terminology?

• Retest period applies to marketed finished product; shelf life applies only to active substances
• Retest period is the time within which bulk drug substance should be retested; shelf life is the labelled expiry time for the finished product
• They are identical terms and can be used interchangeably
• Retest period is always longer than shelf life

Correct Answer: Retest period is the time within which bulk drug substance should be retested; shelf life is the labelled expiry time for the finished product

Q9. Which primary packaging property most directly affects moisture ingress and therefore product stability?

• Color of the packaging ink
• Water vapor transmission rate (WVTR) of the container closure system
• Brand name printed on the carton
• Shape of the secondary carton

Correct Answer: Water vapor transmission rate (WVTR) of the container closure system

Q10. What defines a “stability‑indicating” analytical method?

• An assay that is simpler than the compendial method
• An analytical procedure that separates and quantifies the active moiety in presence of degradation products, impurities and excipients
• A dissolution test that ignores degradation products
• Any chromatographic method that uses a UV detector

Correct Answer: An analytical procedure that separates and quantifies the active moiety in presence of degradation products, impurities and excipients

Q11. According to WHO guidance, what is the typical recommended storage temperature range for many vaccines during the cold chain?

• −20°C to −10°C
• 2°C to 8°C
• 15°C to 25°C
• Room temperature without controls

Correct Answer: 2°C to 8°C

Q12. How much long-term stability data does ICH Q1A(R2) generally recommend should be available at the time of initial registration?

• No long-term data required at submission
• At least 12 months of long-term stability data
• Exactly 36 months of long-term data only
• Only accelerated data are acceptable at submission

Correct Answer: At least 12 months of long-term stability data

Q13. For which situations are bracketing and matrixing designs most appropriately applied?

• For single-strength products only
• When multiple strengths, container sizes, or packaging configurations exist and testing all combinations is impractical
• Only for clinical trial formulations with no commercial intent
• When the product is intended only for hospital use

Correct Answer: When multiple strengths, container sizes, or packaging configurations exist and testing all combinations is impractical

Q14. What statistical approach does ICH Q1E recommend for evaluating stability data to assign shelf life?

• Simple observation without statistics
• Regression analysis and estimation of the time when acceptance criteria are no longer met
• ANOVA with no trend analysis
• Chi-square test applied to potency values

Correct Answer: Regression analysis and estimation of the time when acceptance criteria are no longer met

Q15. Which products are subject to photostability testing under ICH Q1B?

• Only injectable biologicals
• All new drug substances and products to determine photostability characteristics
• Only products with visible color change
• Only products stored below 0°C

Correct Answer: All new drug substances and products to determine photostability characteristics

Q16. Which ICH guideline specifically addresses stability testing for biotechnology‑derived pharmaceuticals?

• ICH Q1A
• ICH Q5C
• ICH Q8
• ICH Q9

Correct Answer: ICH Q5C

Q17. What is a primary advantage of using a matrixing design in stability programs?

• It eliminates the need for a stability protocol
• It reduces the total number of samples and analyses required while still providing representative stability information
• It increases the number of required stability tests for every timepoint
• It replaces the requirement for photostability testing

Correct Answer: It reduces the total number of samples and analyses required while still providing representative stability information

Q18. Which chemical stress conditions are commonly used in forced degradation studies?

• Hydrolysis (acid/base), oxidation, thermal stress and photolysis
• Only refrigeration and freezing
• Only neutral water exposure at room temperature
• Packaging drop tests and vibration only

Correct Answer: Hydrolysis (acid/base), oxidation, thermal stress and photolysis

Q19. In regulatory terms, the “container-closure system” is important because it:

• Determines only the marketing appearance of the product
• Is the physical barrier that can affect product stability through moisture, oxygen ingress, and interaction with the product
• Is irrelevant once the product is manufactured
• Refers only to the secondary cardboard carton

Correct Answer: Is the physical barrier that can affect product stability through moisture, oxygen ingress, and interaction with the product

Q20. Under ICH Q1E, what method is commonly used to extrapolate shelf life when sufficient long-term data exist?

• Expert opinion without data
• Linear or appropriate model regression of stability data to estimate time to failure of acceptance criteria
• Using only the earliest timepoint showing any change
• Applying accelerated test results directly without correction

Correct Answer: Linear or appropriate model regression of stability data to estimate time to failure of acceptance criteria

Download